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Chemiluminescent enzyme immunoassay (CLEIA), surface plasmon resonance (SPR) immunoassay and enzyme- 
linked immunosorbent assay (ELISA) were developed for the highly sensitive detection of human albumin (HA). The 
bioanalytical procedure, involving the surface modification and antibody immobilization, was the same for all 
immunoassay formats. The bioanalytical platforms, i.e. microtiter plates (MTP) and SPR gold chips, were initially 
functionalized with 3-aminopropyltriethoxysilane and then crosslinked to anti-HA antibodies using 1-ethyl-3-[3- 
dimethylaminopropyl]  carbodiimide  hydrochloride  and  sulfo-N-hydroxysuccinimide.  The  developed  HA 
immunoassay formats were compared on the basis of their analytical performance. CLEIA was found to be the best 
format for HA detection as it had the highest analytical sensitivity with lowest limit of detection and widest dynamic 
range. The analytical sensitivity of various immunoassay formats were in the decreasing order of CLEIA > ELISA > 
SPR. The developed CLEIA for HA detection was 6-fold more sensitive than the widely used commercially-available 
ELISA. The anti-HA antibody bound MTPs, stored at 4°C in 0.1M PBS, pH 7.4, were stable for up to 4 weeks, and 
can be effectively used for the rapid detection of HA in just 2.5 h. 
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The precise determination of human albumin (HA) concentration is important for biomedical 
diagnostics and for monitoring the efficacy of treatment regimens. Human serum albumin (HSA) is a 
soluble monomeric protein produced in the liver. It is the most abundant protein in human blood plasma, 
which comprises about half of the blood serum protein. The HSA concentration in normal humans is 
between 25-50 mg/mL. The HSA levels are decreased in case of kidney disease [1], liver disease [2], 
inflammation [3], malnutrition [4], shock [5], nephrotic syndrome, diabetic nephropathy, burns, 
malabsorption, malignancy,  genetic  variations, rheumatoid arthritis  [6],  late  pregnancy, and 
cardiovascular morbidity and mortality [7]. However, the increased HSA levels are almost always due to 
dehydration [8]. HSA is important in regulating the blood volume by monitoring the colloid osmotic 
pressure and buffering pH of the blood. It also transports many small hydrophobic molecules [9] such as 
bilirubin, progesterone, fatty acids, uric acids, calcium, antibiotics and various drugs in the blood. 
The increased urinary albumin levels in diabetics indicate increased risk of developing end-stage renal 
and cardiovascular diseases [10]. It is also an indicator of the renal damage due to nephrotoxic substances 
[11]. Micoalbuminuria is a predictive marker for diabetic nephropathy. Therefore, the urinary albumin 
levels of diabetics are periodically monitored about three times a year so that the treatment can be 
immediately started after the detection of early stage renal damage. The detection of trace contamination 
of HA in pharmaceutical and other biological products is also equally important for monitoring the 
quality of  in-process streams and  final product, and  for  the  development of  optimized purification 
process. 
Several analytical techniques, based on the use of piezoelectric quartz crystal [12], capillary 
electrophoresis [13], fluorescent dyes [14], ELISA [15], microfluidics [16], total internal reflected 
resonance light scattering [17], radial immunodiffusion [18], immunonephelometry [19], radio 
immunoassay [20] and immunoturbidimetric method [21], have been employed for the determination of 
HA. ELISA, SPR and CLEIA are the most commonly used immunoassay formats for disease diagnosis. 
ELISA has been the most widely used format for disease diagnosis from the last four decades, which is 
still being used on a very large scale due to its convenience, high sensitivity and specificity. On the other 
hand, the use of CLEIA and SPR immunoassay for disease diagnosis has increased considerably during 
the last decade. CLEIA provides very high assay sensitivity based on the availability of several highly 
sensitive chemiluminescent substrates [22], whereas SPR based instruments enables the rapid, real-time, 
and label-free analyte detection in addition to providing the highly useful information about biomolecular 
interactions. CLEIA and ELISA are quite similar as they involve the enzyme-mediated signal 
development. In ELISA, the enzyme-substrate reaction between HRP and TMB leads to the development 
of colorimetric signal. On the other hand, in CLEIA, luminol is used as a chemiluminescent material, 
which is activated by the enzyme-substrate reaction between HRP and H2O2, and oxidized to 3- 
aminophthalate to produce the desired chemiluminescence in its transition states. 
The screening of an appropriate immunoassay format for analyte detection is very important for a 
particular bioanalytical application. Therefore, the main objective of this study is to compare the 
developed CLEIA, ELISA and SPR immunoassay formats for the detection of HA. The same assay 
components present in the commercially-available HA ELISA kit from Bethyl Labs, USA were employed 
for all the formats. The surface modification and antibody-crosslinking procedures were also identical for 
all the formats, where anti-HA antibodies were crosslinked using 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC) and sulfo-N-hydroxysuccinimide (SNHS) to the 3- 
aminopropyltriethoxysilane (APTES)-functionalized bioanalytical platforms. The developed CLEIA was 
found to be the best immunoassay format for HA detection and the most sensitive immunoassay for HA 
detection. 
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Phosphate buffered saline (PBS, 0.1M, pH 7.4), 2-(N-morpholino)ethanesulfonic acid (MES, pH 4.7), 
EDC, SNHS, bovine-serum albumin (BSA), 3,3′,5,5′-tetramethylbenzidine (TMB) substrate kit, 
Supersignal ELISA femto maximum sensitivity substrate and LumiNuncTM 96-well MTP for 
chemiluminescence assays were bought from Thermo Scientific. APTES, absolute ethanol, potassium 
hydroxide (KOH), Tween 20, Nunc 96-well flat bottom MTPs, 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES), H2O2 [30%, (v/v)] and H2SO4 [97.5% (v/v)] were procured from 
Sigma-Aldrich. The HA kit containing all sandwich ELISA components was procured from Bethyl Labs, 
USA. Anti-HA antibodies and horseradish peroxidase (HRP)-labeled anti-HA antibodies were employed 
as capture and detection antibodies, respectively. Ultrapure water (UPW) (18 MΩ, Direct Q, Millipore) 
was used for preparing buffers, KOH and 3-APTES; 0.1M MES buffer, pH 4.7 was employed to 
reconstitute EDC and SNHS; ELISA coating buffer (0.05 M carbonate-bicarbonate, pH 9.6) was used for 
diluting anti-HA antibodies; and, sample/conjugate diluent (50 mM Tris, 0.14 M NaCl, 1% BSA, 0.005% 
Tween 20) was used for reconstituting HA and HRP-labeled anti-HA antibodies. ELISA coating buffer 
(0.05 M carbonate-bicarbonate, pH 9.6), ELISA wash solution (50 mM Tris, 0.14 M NaCl, 0.05% Tween 
20, pH 8.0), ELISA blocking solution (50 mM Tris, 0.14 M NaCl, 1% BSA, 0.05% Tween 20, pH 8.0) 
and sample/conjugate diluent (50 mM Tris, 0.14 M NaCl, 1% BSA, 0.005% Tween 20) were purchased 
from Bethyl Labs, USA. The thermostat was procured from Labnet International Inc., USA, while Tecan 
Infinite M200 Pro MTP reader was bought from Tecan GmbH, Austria. 
SPR was performed on BIAcore 3000 instrument from GE Healthcare, Uppsala, Sweden. The surface 
interaction analysis (SIA) kit Au (BR-1004-05) containing SPR Au chips were purchased from GE 
Healthcare. The SPR Au chip was assembled according to the instructions supplied by the manufacturer. 
10mM HEPES buffered saline (HBS) buffer, pH 7.4 was employed as the running buffer for BIAcore. It 
was prepared, filtered through 0.2μ m Millipore filter paper and degassed overnight in order to remove 
any air bubbles, which may cause interference with SPR analysis. All the sample dilutions were made in 
the running buffer (10mM HBS, pH 7.4). The dilutions of HA were made in BSA-preblocked glass vials, 
prepared by incubating with 1% (w/v) BSA for 30 min, to minimize analyte loss due to non-specific 
adsorption on sample tube surfaces and/or altered immunogenicity [23]. 
 
2.2 Surface modification of microtiter plate and crosslinking of antibody 
 
Each well of the 96-well plate was treated with 100 μ L of absolute ethanol for 5 min at 37°C and 
washed five times with 300 μ L of UPW.  Subsequently, each well was treated with 100 μ L of 1.0% (w/v) 
KOH at 37°C for 10 min followed by five washings with 300 μ L of UPW. The KOH-treated wells were 
then functionalized with amino groups by incubating with 100 μ L of 2% (v/v) APTES per well at room 
temperature (RT) for 1 h inside a fume hood. The amine-functionalized plate was washed five times with 
300 μ L of UPW to remove excess of unbound 3-APTES from the surface. Thereafter, anti-HA antibody 
(990 μ L of 10 μ g/mL) was incubated with a 10 μ L of premixed solution of EDC (4 mg/mL) and SNHS 
(11mg/mL) for 15 min at 37°C. 100 μ L of the resulting EDC-SNHS activated anti-HA antibody solution 
was added to each of the APTES-functionalized wells followed by incubation for 1 h at 37°C.  The anti- 
HA antibody-coated wells were then washed five times with 300 μ L of ELISA wash solution. 




The anti-HA antibody-bound MTP were blocked with ELISA blocking solution for 30 min at 37°C and 
subsequently washed five times with 300 μ L of ELISA wash solution. 100 μ L of each of the varying 
concentrations of HA (6.25-400 ng/mL) were incubated in the anti-HA antibody-coated plates for 1 h at 
37°C followed by washing with 300 μ L of ELISA wash solution five times. 100 μ L of HRP-labeled anti- 
HA detection antibody (diluted 1:75,000 i.e. 13.3 ng/mL) was then added and incubated for 1 h at 37°C 
followed by five washes with 300 μ L of ELISA wash solution. The TMB substrate was then added (as 
per the manufacturer’s guidelines) and the enzyme-substrate colorimetric reaction was allowed to develop 
in the dark for 20 min. The enzyme-substrate reaction was stopped by adding 100 μ L of 0.18 M H2SO4. 
The absorbance was measured at 450 nm with reference at 540 nm.  All the experiments were done in 
triplicate with zero ng/mL HA (in sample/conjugate diluent) as control, whose absorbance was subtracted 





The CLEIA procedure was similar to that of ELISA till the binding of HRP-labeled anti-HA detection 
antibody. However, CLEIA employs chemiluminescent substrate instead of TMB substrate that is used in 
ELISA. The working solution, made by mixing equal parts of luminol/enhancer and stabilizer peroxide 
solution, was subsequently added and incubated for 5 min. The chemiluminescent intensity was measured 
with Tecan Infinite M200 Pro’s chemiluminescence readout at 425 nm. All the experiments were carried 
out in triplicate. The control for this study was zero ng/mL concentration of HA (in sample/conjugate 
diluent), whose reading was subtracted from all the assay values. The conventional CLEIA procedure was 
exactly similar to that of conventional ELISA with the exception of enzyme-substrate reaction. 
 
2.5 SPR immunoassay 
 
SPR based HA immunoassay was performed using our previously developed covalent procedure [24]. 
The cleaned SPR Au chip was incubated with 100 μ L of 2% (v/v) APTES for 1 h at RT in a fume hood 
and washed extensively with DIW. EDC-activated anti-HA antibody was prepared by incubating anti-HA 
antibody [990 μ L of 100 μ g/mL in 10 mM HEPES buffered saline (HBS), pH 7.4] at RT for 15 min with 
10 μ L of cross-linking solution containing EDC (4 mg/mL) and sulfo-NHS (11 mg/mL) in 0.1 M MES, 
pH 4.7. Fifty microliters of EDC-activated anti-HA antibody was then injected over all the flow cells of 
APTES-functionalized Au chip at 10 μ L/min. The non-specific binding sites on the chip were blocked by 
treatment with 20 μ L of 1% (w/v) BSA. The change in SPR response units (RU) for the blanks were 
obtained by passing 50 μ L of 10 mM HBS, pH 7.4 through all the flow cells. Thereafter, 50 μ L of HA at 
seven different dilutions (6.2, 12.5, 25, 50, 100, 200 and 400 ng/mL) were passed through the flow cells. 
The  change  in  RU  for  the  blanks  were  subtracted  from  the  change  in  RU  for  captured  HA  of 
corresponding flow cells. The most widely used carboxymethyl (CM5) dextran chip based immunoassay 
procedure, as described previously [24], was employed as conventional SPR immunoassay for HA. 
 
2.6 Data analysis 
 
SigmaPlot software, version 11.2 was employed to plot the immunoassay curves of developed CLEIA, 
ELISA and SPR immunoassays for HA detection using a four-parameter logistic function based standard 
curve analysis. The  EC50, Rsqr  and  hillslope were  determined from the  software report, while the 
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analytical sensitivity was calculated by [mean absorbance of blank + 3(standard deviation of the blank)]. 
The variability of the assay was reported as percentage coefficient of variation (%CV), while the intra- 
assay and inter-assay variability were determined from five assay repeats (in triplicate) on a single and 




Fig. 1. Schematic of the bioanalytical procedure employed for the developed HA immunoassay formats for the covalent binding of 
capture anti-HA antibody to the APTES-functionalized bioanalytical platforms. 
 
3.    Results and Discussion 
 
CLEIA, ELISA and SPR immunoassay formats for HA detection were developed using the same 
bioanalytical procedure that involved the silanization of substrates and covalent crosslinking of antibody. 
The various formats were then compared based on their analytical performance. Many studies have 
demonstrated that SPR immunoassays are comparable to ELISA in terms of analyte detection and 
sensitivity [25-27]. But they employed different surface modification and antibody immobilization 
procedures for ELISA and SPR, which added additional experimental parameters and thus, limited the 
actual analytical comparison of these techniques. Therefore, we have compared the various HA 
immunoassay formats by using the same bioanalytical procedure [Fig. 1] and assay components under the 
same assay conditions. The bioanalytical procedure employed for the surface modification and 
crosslinking of antibodies was derived by the customization of our previously developed procedure, 
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which had been used extensively by us for the development of rapid and highly-sensitive ELISAs [28- 
30], and SPR immunoassays [24, 31, 32]. 
As shown in Fig. 2 and Table 1, the developed CLEIA was the best immunoassay format for HA 
detection. It had wide dynamic range of 0.2-400 ng/mL with the lower limit of detection (LOD) of 0.3 
ng/mL and the high analytical sensitivity of 1 ng/mL. The analytical sensitivity of various immunoassay 
formats  were  in  the  decreasing  order  of  CLEIA  >  ELISA  >  SPR.  The  maximal  half-effective 
concentration (EC50), which also corresponds directly to the sensitivity of an assay, followed the same 
trend  i.e.  CLEIA  >  ELISA  >  SPR.  All  the  developed  immunoassay formats  were  better  than  the 
respective conventional formats in terms of enhanced signal, wide dynamic range and high analytical 
sensitivity. This was mainly due to the leach-proof covalent crosslinking of anti-HA antibody to APTES- 
functionalized bioanalytical platforms that led to greater antibody immobilization density. The developed 
CLEIA for HA detection was 6-fold more sensitive than the widely used commercially-available 
conventional ELISA-based diagnostic kit. The inter-day and intra-day variability of the developed CLEIA 
for various concentrations of HA were between 2-15% and 1-11%, respectively, which were well within 
the acceptable range of less than 20% according to the bioanalytical method validation guidelines issued 
by US Food and Drug Administration (FDA). 
 
Fig. 2. Developed (a) CLEIA, (b) ELISA, and (c) SPR immunoassay formats, for the detection of human albumin. The CLEIA and 
ELISA formats were compared with the conventional passive-adsorbed antibody based formats, while SPR immunoassay was 
compared with the most widely used carboxymethyl (CM5)-dextran chip based conventional format. (d) Stability of the anti-HFA 
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antibody-bound microtiter plates for the detection of HA using the developed CLEIA format. All experiments were done in 
triplicate. The error bars represents standard deviations. 
 
Table 1.  Analytical comparison of the developed immunoassay formats for the detection of human albumin. 
 
Analytical Parameters CLEIA SPR ELISA Conventional 
ELISA 
Detection Range (ng/mL) 0.2-400 6.2-400 1.6-400 6.2-400 
LOD (ng/mL) 0.3 7 1.6 3.2 
Analytical Sensitivity (ng/mL) 1.0 12 3.0 6.2 
EC50 (ng/mL) 
% CV 
31 145 121 215 
Intra-day 1-11 4-12 1-11 2-17 
Inter-day 2-15 3-11 2-13 3-18 
 
Table 2. A comparative analysis of the developed immunoassay formats for the detection of HA with various commercially- 
available HA ELISA kits. 
 
Manufacturer Antibody immobilization 
technique 
LOD* Refer to 
CLEIA                                                       Chemical crosslinking             0.3 ng/mL        Reported here 
ELISA                                                        Chemical crosslinking             1.6 ng/mL        Reported here 
SPR immunoassay                                     Chemical crosslinking             7 ng/mL           Reported here 
Bethyl Laboratories, Inc., USA                 Passive adsorption                   3.2 ng/mL        Reported here 
Alpha Diagnostic International, USA Passive adsorption 10 ng/mL http://www.4adi.com GenWay 
Biotech, USA Passive adsorption 4.11 ng/mL http://www.genwaybio.com 
Cayman, USA  250 ng/mL http://www.caymanchem.com 
Cygnus Technologies, USA 2 ng/mL http://www.cygnustechnologies.com 
Uscn Life Science Inc., China 1.23 μ g/mL http://www.uscnk.com 
AssayPro, USA 0.39 μ g/mL http://www.assaypro.com 
Biorbyt, UK 3.12 ng/mL http://www.biorbyt.com 
Antibodies-online GmbH, USA 4 μ g/mL http://www.antibodies-online.com 
Innovative Research, Inc., USA 6.25 ng/mL http://www.irbiologicals.com 
Immunology Consultants Laboratory, 
Inc., USA 
6.25 ng/mL http://www.immunesystems.co.uk 
Bio-Quant Diagnostic Kits, USA 5 mg/mL http://www.bqkits.com 
Abnova Corporation, Taiwan 3.12 ng/mL http://www.abnova.com 
CusabioBiotech Co., Ltd., China 78 μ g/mL http://www.cusabio.cn 
 
Our results for SPR immunoassay and ELISA are complementary to the previous reports [33, 34] 
stating the higher sensitivity of ELISA in comparison to that of SPR immunoassay. But they contradict 
the findings of other reports, where SPR immunoassay was observed to be more sensitive than ELISA 
[35]. However, it is difficult to make a precise comparison as researchers have employed different assay 
steps and chemistries for these formats. Therefore, our results, based on the use of same bioanalytical 
procedure for various immunoassay formats, provide a more precise comparison of various analytical 
techniques. Our results demonstrating the higher sensitivity of CLEIA in comparison to ELISA agree 
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with the previous reports [36-38], where the LOD and sensitivity of CLEIA were 2-8 fold better than that 
of ELISA, when passively adsorbed antibody was used in both the formats. However, they are contrary to 
other reports [39], where there was no difference in the sensitivity and specificity of CLEIA and ELISA. 
The anti-HA antibody bound MTP can be effectively stored at 4°C in 0.1M PBS, pH 7.4 for up to 4 
weeks without any significant decrease in the chemiluminescent signal corresponding to the detection of 
HA by the developed CLEIA [Fig. 2(d)]. Therefore, the developed CLEIA is ideal for potential end-user 
applications in healthcare and industrial settings as it enables HA detection in just 2.5 h using prebound 
anti-HA antibody-coated MTPs. It is the best immunoassay format in comparison to developed ELISA, 
developed SPR immunoassay and widely used commercially-available conventional ELISA. To our 
knowledge, it is the most sensitive assay for HA detection [Table 2]. 
 
3.    Conclusions 
 
CLEIA, ELISA and SPR immunoassay formats were developed for the highly sensitive detection of 
HA using the same bioanalytical procedure, which involved the APTES-functionalization of bioanalytical 
platforms and the covalent crosslinking of anti-HA antibody. The various formats were compared on the 
basis of their analytical performance using the same assay components. The developed HA CLEIA was 
the best immunoassay format in terms of highest analytical sensitivity and widest detection range. The 
anti-HA antibody bound microtiter plates stored at 4°C in 0.1M PBS, pH 7.4 were stable for up to 4 
weeks and enabled HA detection in just 2.5 h. The developed CLEIA is the most sensitive assay for the 
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